Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Bristol-Myers pays $300 million for Cambridge biotech

By , Globe Staff

Drug giant Bristol-Myers Squibb Co. has agreed to pay $300 million to buy a two-year-old Cambridge biotech developing treatments for cancers and other diseases.

Vertex reports strong findings from cystic fibrosis drug trials

By , Globe Staff

A combination treatment dramatically improved lung function, lifting hopes for a medicine that could treat 90 percent of CF patients.

With ads, rare for a medical device maker, Boston Scientific shifts gears

By , Globe Staff

The Marlborough medical device company is moving into the fast-growing cardiology markets.

Vertex hikes price of cystic fibrosis drug

By , Globe Staff

Boston biotech Vertex Pharmaceuticals Inc. has boosted the list price of its best-selling cystic fibrosis treatment, called Orkambi, by 5 percent to $272,697 a year per patient.